Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer

BJU International

Volumn 95, Issue 6, 2005, Pages 776-779

  Weston, Robin ^a,b   Hussain, Asad ^a   George, Emmanuel ^a   Parr, Nigel J ^a  

^a ARROWE PARK HOSPITAL   (United Kingdom)

^b WIRRAL UNIVERSITY TEACHING HOSPITAL   (United Kingdom)

Author keywords

Hormone therapy; Osteoporosis; Prostate carcinoma; Testosterone

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; GONADORELIN DERIVATIVE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; BONE DEMINERALIZATION; BONE DENSITOMETRY; BONE DENSITY; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FOREARM; HUMAN; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BONE DENSITY; DENSITOMETRY, X-RAY; GOSERELIN; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 17444371226     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05399.x     Document Type: Conference Paper

References (20)

1. Sarosdy MF, Schellhammer PF, Soloway MS et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. BJU Int 1999; 83: 801-6
2. Daniell HW, Dunn SR, Ferguson DW et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-6
3. Stoch SA, Parker RA, Chen L et al. Bone loss in men with prostate cancer treated with gonadatropin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86: 2787-91
4. Townsend MF, Sanders WH, Northway RO et al. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 1997; 79: 545-50
5. Hatano T, Oishi Y, Furuta A et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 2000; 86: 449-52
6. Tyrrell CJ, Kaisary AV, Iversen P et al. A randomised comparison of 'Casodex' 150mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998; 33: 447-56
7. Iversen P, Tyrrell CJ, Kaisary AV et al. Casodex 150mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer, results from two multicenter randomised trials at a median follow-up of 4 years. Urology 1998; 51: 389-96
8. Stoch SA, Parker RA, Chen L et al. Bone loss in men with prostate cancer treated with gonadctrophin-releasing hormone agonists. J Clin Endocrinol Metab 2001; 86: 2787-91
9. Goldray D, Weisman Y, Jaccard N et al. Decreased bone density in elderly men treated with the gonadotrophin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab-1993; 76: 288-90
10. Harry DW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439-44
11. Smith EP, Boyd J, Frank GR et al. Oestrogen resistance caused by a mutation in the oestrogen receptor gene in man. N Engl J Med 1994; 331: 1056-61
12. Percival RC, Urwin GH, Harris S et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987; 13: 41-9
13. Charhon SA, Shapuy MC, Delvin EE et al. Histomorphometric analysis of sclerotic bone metastasis from prostatic carcinoma with special reference to osteomalacia. Cancer 1983; 51: 918-24
14. Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate DEXA scanning reveals a high incidence of osteoporosis in advanced prostate cancer prior to hormonal manipulation. BJU Int 2003; 92: 690-4
15. Ray NF, Chan JK, Thamer M et al. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 24-35
16. Verhelst J, Denis L. Van Vliet P et al. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol 1994; 41: 525-30
17. Pickles T, Agranovich A, Berthelet E et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate cancer. Cancer 2002; 94: 362-7
18. Nejat RJ, Rashid HH, Bagiella E et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000; 164: 1891-4
19. Hall CM, Fritzsch RJ, Sagalowsky AI et al. Prospective determination of the hormonal response after cessation of luteinising hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 1999; 53: 898-903
20. Amin S, Zhang Y, Sawin CT et al. Association of hypogonadism and estradiol levels with bone mineral density in elderley men from the Framingham Study. Ann Intern Med 2000; 133: 951-63